Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2291 07/06/2021 ramucirumab (Cyramza) Non submission

In combination with erlotinib is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutations
1190/16 12/09/2016 bevacizumab (Avastin) Non submission In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.
749/11 16/01/2012 erlotinib (Tarceva) Full first line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR
664/10 17/01/2011 erlotinib (Tarceva) Full Maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease after 4 cycles of standard platinum-based first-line chemotherapy
382/07 09/07/2007 Erlotinib (Tarceva) Non submission metastatic pancreatic cancer
220/05 05/06/2006 Erlotinib (Tarceva®) Resubmission Locally advanced or metastatic non small cell lung cancer after failure of at least one prior chemotherapy regimen
220/05 12/12/2005 Erlotinib (Tarceva®) Full Locally advanced or metastatic non small cell lung cancer after failure of at least one prior chemotherapy regimen

No medicines have been found.